Announcement PDF Appendix 3B - Proposed issue of securities Announcement Summary Entity name AMPLIA THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement 16/4/2024 The Proposed issue is: A standard pro rata issue (including non-renounceable or renounceable) Total number of +securities proposed to be issued for a standard pro rata issue (including non-renounceable or renounceable) ASX +security code +Security description ATX ORDINARY FULLY PAID Maximum Number of +securities to be issued 77,602,558 Ex date 18/4/2024 +Record date 19/4/2024 Offer closing date 8/5/2024 Issue date 15/5/2024 Refer to next page for full details of the announcement Appendix 3B - Proposed issue of securities 1/7 Appendix 3B - Proposed issue of securities Part 1 - Entity and announcement details 1.1 Name of +Entity AMPLIA THERAPEUTICS LIMITED We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules. If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation). 1.2 Registered Number Type Registration Number ABN 16165160841 1.3 ASX issuer code ATX 1.4 The announcement is New announcement 1.5 Date of this announcement 16/4/2024 1.6 The Proposed issue is: A standard +pro rata issue (non-renounceable or renounceable) 1.6a The proposed standard +pro rata issue is: + Non-renounceable Appendix 3B - Proposed issue of securities 2/7 Appendix 3B - Proposed issue of securities Part 3 - Details of proposed entitlement offer issue Part 3A - Conditions 3A.1 Do any external approvals need to be obtained or other conditions satisfied before the entitlement offer can proceed on an unconditional basis? No Part 3B - Offer details +Class or classes of +securities that will participate in the proposed issue and +class or classes of +securities proposed to be issued ASX +security code and description ATX : ORDINARY FULLY PAID Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)? Existing class Will the proposed issue of this +security include an offer of attaching +securities? No If the entity has quoted company options, do the terms entitle option holders to participate on exercise? No Details of +securities proposed to be issued ASX +security code and description ATX : ORDINARY FULLY PAID ISIN Code (if Issuer is a foreign company and +securities do not have +CDIs issued over them) ISIN Code for the entitlement or right to participate in a non-renounceable issue (if Issuer is foreign company and +securities do not have +CDIs issued over them) Offer ratio (ratio to existing holdings at which the proposed +securities will be issued) The quantity of additional +securities For a given quantity of +securities to be issued held 2 Appendix 3B - Proposed issue of securities 5 3/7 Appendix 3B - Proposed issue of securities What will be done with fractional entitlements? Maximum number of +securities proposed to be issued (subject to rounding) Fractions rounded up to the next whole number 77,602,558 Offer price details for retail security holders In what currency will the offer be made? What is the offer price per +security for the retail offer? AUD - Australian Dollar AUD 0.05500 Oversubscription & Scale back details Will individual +security holders be permitted to apply for more than their entitlement (i.e. to over-subscribe)? Yes Describe the limits on over-subscription The Entitlement Offer incorporates a Shortfall Facility under which Eligible Shareholders can apply for Additional New Shares up to a cap of 100% of their pro rata Entitlement. The issue of Additional New Shares will be dependent on there being a shortfall in the take up of pro rata Entitlements under the Entitlement Offer. Will a scale back be applied if the offer is over-subscribed? Yes Describe the scale back arrangements In the event the Shortfall is less than the number of Shortfall Shares applied for by applicants, scale back will apply to applicants under the Shortfall Facility. The scale-back among those Applicants will be considered and determined at the Board's discretion, in consultation with the Lead Manager, taking into account the total Shortfall, the number of Shortfall Shares applied for and each Applicant's current shareholding. Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class? Yes Part 3C - Timetable 3C.1 +Record date 19/4/2024 3C.2 Ex date 18/4/2024 3C.4 Record date 19/4/2024 3C.5 Date on which offer documents will be sent to +security holders entitled to participate in the +pro rata issue Appendix 3B - Proposed issue of securities 4/7 Appendix 3B - Proposed issue of securities entitled to participate in the +pro rata issue 24/4/2024 3C.6 Offer closing date 8/5/2024 3C.7 Last day to extend the offer closing date 3/5/2024 3C.9 Trading in new +securities commences on a deferred settlement basis 9/5/2024 3C.11 +Issue date and last day for entity to announce results of +pro rata issue 15/5/2024 3C.12 Date trading starts on a normal T+2 basis 16/5/2024 3C.13 First settlement date of trades conducted on a +deferred settlement basis and on a normal T+2 basis 20/5/2024 Part 3E - Fees and expenses 3E.1 Will there be a lead manager or broker to the proposed offer? Yes 3E.1a Who is the lead manager/broker? Taylor Collison Limited 3E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker? The Lead Manager will receive: (i) an underwriting fee equal to 4.0% of the gross Entitlement Offer proceeds less that part of the Entitlement Offer proceeds that is taken up by, or sub-underwritten by, a Director; (ii) a management fee of 2.0% of the gross Entitlement Offer proceeds; and (iii) 3,500,000 unlisted options, each of which is exercisable for one New Share at an exercise price of $0.135 and an expiry date of 5 June 2028. 3E.2 Is the proposed offer to be underwritten? Yes 3E.2a Who are the underwriter(s)? Taylor Collison Limited 3E.2b What is the extent of the underwriting (ie the amount or proportion of the offer that is underwritten)? 100% 3E.2c What fees, commissions or other consideration are payable to them for acting as underwriter(s)? The Lead Manager will receive: (i) an underwriting fee equal to 4.0% of the gross Entitlement Offer proceeds less that part of the Entitlement Offer Proceeds that is taken up by, or sub-underwritten by, a Director; (ii) a management fee of 2.0% of the gross Entitlement Offer proceeds; and Appendix 3B - Proposed issue of securities 5/7 Appendix 3B - Proposed issue of securities (iii) 3,500,000 unlisted options, each of which is exercisable for one New Share at an exercise price of $0.135 and an expiry date of 5 June 2028. 3E.2d Please provide a summary of the significant events that could lead to the underwriting being terminated Refer to investor presentation dated 16 April 2024 which is available on www.asx.com.au 3E.2e Is a party referred to in listing rule 10.11 underwriting or sub-underwriting the proposed offer? Yes 3E.2e (i) What is the name of that party? Robert Peach 3E.2e (ii) What is the extent of their underwriting or sub-underwriting (ie the amount or proportion of the offer they have underwritten or sub-underwritten)? 149,999.96 3E.2e (iii) What fee, commission or other consideration is payable to them for acting as underwriter or sub-underwriter? Nil 3E.3 Will brokers who lodge acceptances or renunciations on behalf of eligible +security holders be paid a handling fee or commission? No 3E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed offer N/A Part 3F - Further Information 3F.1 The purpose(s) for which the entity intends to use the cash raised by the proposed issue Pre-clinical studies (cancer), Phase 1 (Pilot Investigator Initiated) clinical trial - Ovarian Cancer, Phase 2a clinical trial Pancreatic Cancer, Drug capsule manufacture, IP and licences, Cash costs of the Entitlement Offer and working capital. 3F.2 Will holdings on different registers or subregisters be aggregated for the purposes of determining entitlements to the issue? No 3F.3 Will the entity be changing its dividend/distribution policy if the proposed issue is successful? No 3F.4 Countries in which the entity has +security holders who will not be eligible to participate in the proposed issue Canada, Liechtenstein, Singapore, Spain, Swaziland, Switzerland, United Kingdom, United States of America 3F.5 Will the offer be made to eligible beneficiaries on whose behalf eligible nominees or custodians hold existing +securities Yes 3F.5a Please provide further details of the offer to eligible beneficiaries Nominees and custodians may not distribute any part of the Offer Booklet or any Entitlement and Acceptance Form in any country outside Australia or New Zealand, except to beneficial holders of Shares in Australia or New Zealand, and beneficial holders of Shares who are institutional or professional investors in other countries that the Company has approved as being a country in which investors are eligible to participate, as well as any other country to the extent the Company may determine it is lawful and practical to make the Entitlement Offer. 3F.6 URL on the entity's website where investors can download information about the proposed issue https://www.ampliatx.com/site/news-and-reports/ASX-Announcements 3F.7 Any other information the entity wishes to provide about the proposed issue 3F.8 Will the offer of rights under the rights issue be made under a +disclosure document or product disclosure statement under Chapter 6D or Part 7.9 of the Corporations Act (as applicable)? Appendix 3B - Proposed issue of securities 6/7 Appendix 3B - Proposed issue of securities statement under Chapter 6D or Part 7.9 of the Corporations Act (as applicable)? No 3F.9 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of: The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f) Appendix 3B - Proposed issue of securities 7/7